Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
VolitionRX ( (VNRX) ) has provided an announcement.
On March 31, 2026, VolitionRx Limited shareholders met in London and approved the issuance of additional common shares exceeding 20% of shares outstanding to Lind Global Asset Management XII LLC, in order to comply with NYSE American listing requirements. At the same special meeting, investors also approved an amendment to authorize a reverse stock split in a ratio between 1-for-5 and 1-for-20, giving the board flexibility to manage the share price and share count, with implications for capital structure, trading liquidity, and continued market listing.
The meeting drew participation from stockholders representing roughly 59% of the company’s outstanding shares, underscoring significant investor engagement in decisions affecting dilution and capital strategy. No other items were brought to a vote, indicating the focus was squarely on securing shareholder backing for key measures that may support VolitionRx’s financing capacity and compliance with exchange rules.
The most recent analyst rating on (VNRX) stock is a Hold with a $0.19 price target. To see the full list of analyst forecasts on VolitionRX stock, see the VNRX Stock Forecast page.
Spark’s Take on VNRX Stock
According to Spark, TipRanks’ AI Analyst, VNRX is a Neutral.
The score is held down primarily by weak financial performance (large losses, persistent cash burn, and negative equity). Technicals also reflect a weak longer-term trend, while valuation offers limited support given negative earnings. Offsetting these factors, the latest earnings call was moderately positive due to partnerships, commercialization progress, and cost control, but uncertainty around revenue timing remains a key risk.
To see Spark’s full report on VNRX stock, click here.
More about VolitionRX
VolitionRx Limited operates in the healthcare and life sciences sector, focusing on developing and commercializing diagnostic technologies based on blood tests. The company’s work centers on cancer and other disease detection, positioning it within the broader diagnostics market and making access to capital and stock exchange compliance strategically important for its growth.
Average Trading Volume: 10,952,507
Technical Sentiment Signal: Strong Sell
Current Market Cap: $27.38M
For a thorough assessment of VNRX stock, go to TipRanks’ Stock Analysis page.